<DOC>
	<DOCNO>NCT02182414</DOCNO>
	<brief_summary>Study investigate relative bioavailability 5 new 400 mg tablet formulation ( trial formulation II prototype ) BI 207127 compare current 200 mg BI 207127 tablet formulation ( trial formulation I ) healthy male volunteer aim identify best formulation drug development ( formulation find part / trial part 1 ) investigate effect food relative bioavailability promise one trial formulation II prototype ( food-effect part / trial part 2 ) .</brief_summary>
	<brief_title>Relative Bioavailability BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male accord complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age 18 50 year , inclusive Body mass index 18.5 29.9 kg/m2 , inclusive Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month prior administration trial drug trial Use drug ( include herbal preparation , vitamin nutrient supplement ) within 14 day prior first administration trial drug trial Participation another trial investigational drug within two month prior administration trial drug trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( 100 mL within four week prior first administration trial drug trial ) Excessive physical activity ( within one week prior first administration trial drug trial drug trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 MS ) A history additional risk factor Torsade de Points ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) History photosensitivity recurrent rash</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>